Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records.

ABSTRACT:

Aim

To evaluate the extent to which balance in unmeasured characteristics of patients with type 2 diabetes (T2DM) was achieved in claims data, by comparing against more detailed information from linked electronic health records (EHR) data.

Methods

Within a large US commercial insurance database and using a cohort design, we identified patients with T2DM initiating linagliptin or a comparator agent within class (ie, another dipeptidyl peptidase-4 inhibitor) or outside class (ie, pioglitazone or a sulphonylurea) between May 2011 and December 2012. We focused on comparators used at a similar stage of diabetes to linagliptin. For each comparison, 1:1 propensity score (PS) matching was used to balance >100 baseline claims-based characteristics, including proxies of diabetes sever

SUBMITTER: Patorno E 

PROVIDER: S-EPMC6207375 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature